Clinical trial · no report yet · Phase 1
NCT05433142
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT05433142 ↗
- Recruiting
- Xencor, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- XmAb819
- Arms
- Dose Escalation and Expansion · Experimental
- Enrollment
- 307 (estimated)
- Primary outcomes
- Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)
- Incidence of dose limiting toxicities (DLTs)
- Sponsor
- Xencor, Inc.
- Start
- Jun 13, 2022
- Primary completion
- Feb 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05433142 · updated Aug 3, 2026